Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19

Christian A Merlo, Hela Romdhani, Maral DerSarkissian, Aruna Muthukumar, Lisa J McGarry, Yiyue Lou, Kate Van Brunt · 2026

Read Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19 by Christian A Merlo, Hela Romdhani, Maral DerSarkissian, Aruna Muthukumar, Lisa J McGarry, Yiyue Lou, Kate Van Brunt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13287179.txt.

Description

Christian A Merlo and co-authors present a 2026 study of a triple-drug therapy for cystic fibrosis, judged against patients who could not take it. The drug combo launched in the United States just as COVID-19 hit, which changed how patients sought care and cut the spread of chest infections for everyone. A plain before-and-after study would credit the drug with the pandemic's effects.

The team instead compared treated patients with untreated patients who were ineligible for the drug, over the same months, using the national cystic fibrosis registry. Tracking both groups side by side strips out the shared pandemic backdrop. The design shows how to judge a drug honestly when history will not sit still.

Catalog record

CREATORChristian A Merlo, Hela Romdhani, Maral DerSarkissian, Aruna Muthukumar, Lisa J McGarry, Yiyue Lou, Kate Van Brunt
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13287179

Browse the full library · About the Tower of Babel